Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients
- 16 January 2009
- journal article
- research article
- Published by Elsevier BV in Atherosclerosis
- Vol. 205 (2), 544-548
- https://doi.org/10.1016/j.atherosclerosis.2008.12.016
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in DiabetesDiabetes, 2008
- A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)The FASEB Journal, 2008
- Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetesMicrovascular Research, 2008
- Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 proteinThe FASEB Journal, 2006
- Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery diseaseDiabetes/Metabolism Research and Reviews, 2006
- Role of HMGB1 in cardiovascular diseasesCurrent Opinion in Pharmacology, 2006
- Increased Expression of the DNA-Binding Cytokine HMGB1 in Human Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Inflammation in atherosclerosisNature, 2002
- Release of chromatin protein HMGB1 by necrotic cells triggers inflammationNature, 2002
- N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene ExpressionJournal of Biological Chemistry, 1999